CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025 08:00 ET
|
CAMP4 Therapeutics
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense...
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
January 07, 2025 16:05 ET
|
CAMP4 Therapeutics
Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two...
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
December 10, 2024 08:00 ET
|
CAMP4 Therapeutics
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting...
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
December 02, 2024 08:00 ET
|
CAMP4 Therapeutics
CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting...
CAMP4 Reports Third Quarter 2024 Financial Results
November 21, 2024 16:05 ET
|
CAMP4 Therapeutics
- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in...
CAMP4 Announces Pricing of Initial Public Offering
October 10, 2024 19:07 ET
|
CAMP4 Therapeutics
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting...
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
March 21, 2024 07:58 ET
|
CAMP4 Therapeutics
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D